US 12,404,252 B2
Salt of 2-amino-2-(2-(1-decyl-1H-1,2,3-triazol-4-yl)ethyl)propane-1,3-diol, and pharmaceutical composition containing same
Bongyong Lee, Seoul (KR); Yanghae Park, Seoul (KR); and Eunjeong Kim, Seongnam-si (KR)
Assigned to NEXTGEN BIOSCIENCE CO., LTD, Gyeonggi-Do (CN)
Appl. No. 18/688,333
Filed by NEXTGEN BIOSCIENCE CO., LTD, Seongnam-si (KR)
PCT Filed Nov. 4, 2022, PCT No. PCT/KR2022/017235
§ 371(c)(1), (2) Date Feb. 29, 2024,
PCT Pub. No. WO2023/080708, PCT Pub. Date May 11, 2023.
Claims priority of application No. 10-2021-0150651 (KR), filed on Nov. 4, 2021.
Prior Publication US 2024/0336578 A1, Oct. 10, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 249/04 (2006.01); A61K 31/4192 (2006.01); A61P 1/00 (2006.01); A61P 17/14 (2006.01)
CPC C07D 249/04 (2013.01) [A61K 31/4192 (2013.01); A61P 1/00 (2018.01); A61P 17/14 (2018.01)] 8 Claims
 
1. A hemifumarate salt of 2-amino-2-(2-(1-decyl-1H-1,2,3-triazol-4-yl)ethyl)propane-1,3-diol, which is a compound represented by Formula 1a below:

OG Complex Work Unit Chemistry